James Quigley
Stock Analyst at Morgan Stanley
(0.55)
# 3,794
Out of 4,711 analysts
20
Total ratings
50%
Success rate
-25.02%
Average return
Main Sectors:
Stocks Rated by James Quigley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Equal-Weight | $45 → $49 | $40.66 | +20.51% | 5 | Nov 6, 2024 | |
| NVS Novartis AG | Downgrades: Neutral | $119 → $121 | $97.11 | +24.60% | 1 | Sep 5, 2024 | |
| GRFS Grifols | Maintains: Neutral | $10 → $11 | $7.51 | +39.81% | 1 | Dec 5, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $42 → $40 | $26.76 | +49.48% | 10 | Aug 7, 2023 | |
| EVO Evotec SE | Upgrades: Overweight | $12 → $16 | $4.47 | +257.94% | 3 | Jun 23, 2023 |
Kymera Therapeutics
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $45 → $49
Current: $40.66
Upside: +20.51%
Novartis AG
Sep 5, 2024
Downgrades: Neutral
Price Target: $119 → $121
Current: $97.11
Upside: +24.60%
Grifols
Dec 5, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $7.51
Upside: +39.81%
Galapagos NV
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $26.76
Upside: +49.48%
Evotec SE
Jun 23, 2023
Upgrades: Overweight
Price Target: $12 → $16
Current: $4.47
Upside: +257.94%